Lercatio

Lercanidipine Hydrochloride, the active ingredient in Lercatio, is a calcium channel blocker presented as an oral dosage form for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension. GNH USA supplies Lercatio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercatio belongs to the calcium channel blocker class and is used to manage high blood pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications associated with sustained hypertension.

Lercatio may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often occurring early in therapy. - Flushing: sensation of warmth and redness, usually transient. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: especially when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or angioedema. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Before initiating therapy, certain considerations are recommended. - Renal impairment: assess kidney function and adjust therapy if needed. - Hepatic disease: monitor liver enzymes and use with caution. - Concomitant antihypertensives: avoid excessive blood pressure lowering. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lercatio can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lercanidipine plasma levels, raising risk of hypotension. - Grapefruit juice: can elevate drug concentration, leading to excessive vasodilation.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive blood pressure reduction. - Simvastatin: lercanidipine may increase statin exposure, raising risk of myopathy. - Beta‑blockers: combined effect on heart rate and blood pressure should be monitored.